Showing results (281-290 of 319) with videos related to
Sort By:
Pageof 32
The Lancet. Oncology|June 23, 2015
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialAndrew X Zhu, Joon Oh Park, Baek-Yeol Ryoo, et al.Science Translational Medicine|April 8, 2011
CD44-SLC1A2 gene fusions in gastric cancerJiong Tao, Nian Tao Deng, Kalpana Ramnarayanan, et al.Oncology|October 19, 2018
Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue SarcomaJee Hung Kim, Hyung Soon Park, Su Jin Heo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortLaura Q M Chow, Robert Haddad, Shilpa Gupta, et al.The Lancet. Oncology|November 18, 2021
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion studyNehal J Lakhani, Laura Q M Chow, Justin F Gainor, et al.Cancer|December 8, 2021
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patientsHyun Cheol Chung, Yoon-Koo Kang, Zhendong Chen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 25, 2019
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Sarina A Piha-Paul, Jose Lopez-Martin, et al.The Lancet. Oncology|September 13, 2020
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyAurélien Marabelle, Marwan Fakih, Juanita Lopez, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2023
Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction CancerChang Gon Kim, Minkyu Jung, Hyo Song Kim, et al.European Journal of Cancer (Oxford, England : 1990)|June 8, 2017
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH studyIan Chau, Markus Peck-Radosavljevic, Christophe Borg, et al.Pageof 32